Story
Synopsys Shares Rise on $1B+ Amazon Deal, OpenAI Partnership, and Raised Guidance
Summary
Synopsys announced a multi-year, $1B+ silicon IP licensing deal with Amazon Web Services and a separate AI partnership with OpenAI, prompting the company to raise its long-term revenue forecast.
Shares of Synopsys (SNPS) surged after the chip design software firm announced a pair of significant strategic deals with Amazon Web Services and OpenAI and raised its long-term revenue growth guidance. The stock was trading up more than 4.6% to approximately $435 in afternoon trading following the announcements at the company's investor summit.
AWS Deal Signals Business Model Shift
Synopsys secured a multi-year agreement valued at over $1 billion with Amazon.com's (AMZN) cloud division, AWS. Under the deal, AWS will license Synopsys' silicon intellectual property (IP) for use in its custom chip development, including its Nitro, Graviton, and Trainium processors.
More significantly for investors, the agreement shifts Synopsys' IP business to a license-plus-royalty model. This structure provides a recurring revenue stream that scales with the production volume of Amazon's chips, a model that markets typically value more highly than one-time license fees. The deal also designates AWS as a lead customer for Synopsys' new application-optimized IP segment, positioning it more directly against competitors like Arm Holdings.
AI Partnership and Upgraded Outlook
AdIn a separate announcement, Synopsys revealed a partnership with OpenAI to develop a specialized AI model called GPT-Synopsys. The model will be trained to execute semiconductor design workflows using Synopsys' electronic design automation (EDA) tools under a shared-revenue framework. CEO Sassine Ghazi noted the initiative represents a new upside to the business rather than a risk of cannibalizing existing revenue.
Backed by these new commercial agreements, Synopsys raised its fiscal year 2027 revenue growth guidance to 15%. According to the source, this new forecast is substantially higher than the analyst consensus of 11.19% compiled by LSEG, providing a concrete catalyst for the day's stock gains.
Market Impact
The series of announcements provides tangible support for the company's strategic pivot and long-term growth narrative. While the stock's intraday high reached $445.57, it remains below its 52-week high of $539.48, according to the provided market data. The positive developments signal a potential revaluation by investors as the company's new royalty-based revenue streams and AI initiatives gain traction.
Read next
More on Stocks
US Transportation Secretary Pushes to Expedite Aircraft Certification Amid China Competition Concerns
Transportation Secretary Sean Duffy stated the U.S. must speed up its aircraft approval process to maintain a competitive edge against China and encourage private investment in aviation innovation. The move follows existing FAA efforts to modernize certification.
Jefferies Identifies Three Biotech Firms with Blockbuster Drug Potential
Investment firm Jefferies has highlighted Delphia Therapeutics, Axsome Therapeutics, and BridgeBio Pharma as undervalued biotech companies with strong late-stage pipelines and significant commercial prospects.
Synopsys Shares Rise on OpenAI Partnership and Strong Revenue Forecast
Chip design software leader Synopsys is partnering with OpenAI on a revenue-sharing basis to develop a specialized AI model for semiconductor design, a move that boosted its stock and financial outlook.
Jefferies Initiates Coverage on Molbio Diagnostics with 'Buy' Rating
Jefferies has initiated coverage on Molbio Diagnostics, naming it a top pick in India's medical supplies sector with a 'Buy' rating and a price target of INR 1,600, citing the strength of its point-of-care diagnostics platform.